Codexis [CDXS] vs Regeneron [REGN] Detailed Stock Comparison

Codexis Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Codexis Inc. wins in 5 metrics, Regeneron Pharmaceuticals, Inc. wins in 14 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Codexis Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) N/A 18.00 N/A
Price-to-Book Ratio 4.52 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 144.88 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio -11.45 -4.80 Regeneron Pharmaceuticals, Inc.
EV/EBITDA -6.77 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) -62.47% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) 35.89% 23.13% Codexis Inc.
EBITDA Margin (TTM) 35.89% 23.13% Codexis Inc.
Return on Equity -74.88% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -16.14% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-23.85M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 20.43% 25.39% Regeneron Pharmaceuticals, Inc.
Price-to-Sales Ratio (TTM) 3.25 5.50 Codexis Inc.
Enterprise Value $223.99M $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 3.18 4.95 Codexis Inc.
Gross Profit Margin (TTM) 94.75% 84.95% Codexis Inc.
Revenue per Share (TTM) $1 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-0.50 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 2.08 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 7.76% 2.55% Regeneron Pharmaceuticals, Inc.

Codexis Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

CDXS
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Codexis Inc.0.74%3.46%7.17%163.73%63.03%67.08%
Regeneron Pharmaceuticals, Inc.2.66%-5.03%-15.02%-23.79%-18.77%-22.36%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Codexis Inc.20.43%5.32%-86.34%-29.87%-73.94%-80.27%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Codexis Inc. vs Regeneron Pharmaceuticals, Inc.

MetricCDXSREGN
Market Information
Market Cap i$228.99M$80.98B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i1,228,754642,495
90 Day Avg. Volume i3,001,368617,765
Last Close$2.71$618.95
52 Week Range$0.96 - $3.87$476.49 - $821.11
% from 52W High-29.97%-24.62%
All-Time High$42.01 (Nov 08, 2021)$1,211.20 (Aug 26, 2024)
% from All-Time High-93.55%-48.90%
Growth Metrics
Quarterly Revenue Growth0.81%0.03%
Quarterly Earnings Growth0.81%-0.08%
Financial Health
Profit Margin (TTM) i-0.62%0.31%
Operating Margin (TTM) i0.36%0.23%
Return on Equity (TTM) i-0.75%0.15%
Debt to Equity (MRQ) i144.889.51
Cash & Liquidity
Book Value per Share (MRQ)$0.56$304.65
Cash per Share (MRQ)$0.86$83.86
Operating Cash Flow (TTM) i$-19,376,000$4.98B
Levered Free Cash Flow (TTM) i$-5,074,125$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Codexis Inc. vs Regeneron Pharmaceuticals, Inc.

MetricCDXS (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A18.00
Forward P/E i-11.4514.21
PEG Ratio i-11.45-4.80
Price to Sales (TTM) i3.255.50
Price to Book (MRQ) i4.522.45
Market Capitalization
Market Capitalization i$228.99M$80.98B
Enterprise Value i$223.99M$70.98B
Enterprise Value Metrics
Enterprise to Revenue i3.184.95
Enterprise to EBITDA i-6.7716.72
Risk & Other Metrics
Beta i2.080.40
Book Value per Share (MRQ) i$0.56$304.65

Financial Statements Comparison: Codexis Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCDXS (2025)REGN (2025)
Revenue/Sales i70.39M14.34B
Cost of Goods Sold i9.34M2.10B
COGS % of Revenue i13.3%14.6%
Gross Profit i61.05M12.24B
Gross Margin i86.7%85.4%
Research & Development i52.31M5.85B
Operating Income (EBIT) i-38.33M3.70B
Operating Margin i-54.5%25.8%
EBITDA i-30.46M5.00B
EBITDA Margin i-43.3%34.8%
Pre-Tax Income i-43.93M5.23B
Pre-Tax Income % of Revenue i-62.4%36.5%
Income Tax i47,000725.80M
Income Tax % of Revenue i0.1%5.1%
Net Income (Profit) i-43.97M4.50B
Profit Margin i-62.5%31.4%

Balance Sheet & Liquidity Metrics

MetricCDXS (2025)REGN (2025)
Cash & Equivalents i50.79M3.12B
Total Current Assets i96.82M18.02B
Total Current Assets % of Revenue i137.5%125.7%
Total Current Liabilities i25.32M4.37B
Total Current Liabilities % of Revenue i36.0%30.5%
Long-Term Debt i70.26M2.71B
Long-Term Debt % of Revenue i99.8%18.9%
Total Shareholders Equity i50.53M31.26B
Retained Earnings i-606.78M35.80B
Retained Earnings % of Revenue i-862.1%249.6%
Property, Plant & Equipment i69.44M1.54B

Cash Flow Statement Comparison

MetricCDXS (2025)REGN (2025)
Operating Cash Flow i-19.68M6.30B
Operating Cash Flow % of Revenue i-28.0%43.9%
Capital Expenditures i-4.47M0
Free Cash Flow i-23.85M3.77B
FCF Margin i-33.9%26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricCDXSREGN
Shares Short i6.94M2.55M
Short Ratio i1.664.46
Short % of Float i7.76%2.55%
Shares Outstanding i90.48M105.72M
Float Shares i72.95M98.55M
% Held by Insiders i7.57%1.98%
% Held by Institutions i74.75%91.08%
% Held by Public i17.68%6.94%

Dividend Analysis & Yield Comparison: Codexis Inc. vs Regeneron Pharmaceuticals, Inc.

MetricCDXSREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026